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A  licensed  malaria  vaccine  would  provide  a  valuable  new  tool  for malaria  control  and  elimination  efforts.
Several  candidate  vaccines  targeting  different  stages  of  the  malaria  parasite’s  lifecycle  are  currently  under
development,  with  one  candidate,  RTS,S/AS01  for the  prevention  of Plasmodium  falciparum  infection,
having  recently  completed  Phase  III trials.  Predicting  the  public  health  impact  of a  candidate  malaria
vaccine  requires  using  clinical  trial  data  to estimate  the  vaccine’s  efﬁcacy  proﬁle—the  initial  efﬁcacy
following  vaccination  and  the  pattern  of waning  of efﬁcacy  over  time.  With an  estimated  vaccine  efﬁcacy
proﬁle,  the effects  of  vaccination  on malaria  transmission  can be  simulated  with  the  aid of  mathematical
models.
Here,  we  provide  an  overview  of  methods  for  estimating  the  vaccine  efﬁcacy  proﬁles  of pre-erythrocytic
vaccines  and  transmission-blocking  vaccines  from  clinical  trial data.  In the  case  of RTS,S/AS01,  model  esti-
mates  from  Phase  II clinical  trial data  indicate  a bi-phasic  exponential  proﬁle  of  efﬁcacy  against  infection,
with  efﬁcacy  waning  rapidly  in  the  ﬁrst  6 months  after  vaccination  followed  by a  slower  rate  of waning
over  the next  4 years.  Transmission-blocking  vaccines  have  yet  to be tested  in  large-scale  Phase II or
Phase  III clinical  trials  so we  review  ongoing  work  investigating  how  a clinical  trial  might  be designed  to
ensure  that  vaccine  efﬁcacy  can  be estimated  with  sufﬁcient  statistical  power.  Finally,  we demonstrate
how  parameters  estimated  from  clinical  trials  can be  used  to predict  the  impact  of  vaccination  campaigns
on  malaria  using  a mathematical  model  of malaria  transmission.. Introduction
Following the declaration of the Millennium Development Goals
n 2000, increased funding for malaria control has resulted in
n estimated 42% reduction in global malaria mortality [1]. This
uccess has been largely attributed to the increased scale up of
overage of long-lasting insecticidal nets (LLINs) and expanded
ccess to effective treatment with Artemisinin Combination Ther-
pies (ACT) [1]. Despite this, the burden of malaria remains high,
ith an estimated 584,000 (367,000–755,000) deaths in 2013, the
ajority in young children in sub-Saharan Africa [1]. Therefore,here remains a pressing need to build on the gains made with
xisting interventions through the development and deployment
f novel tools. Malaria vaccines may  provide a wide range of ben-
ﬁts: providing personal protection from infection and episodes
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of clinical malaria to vaccinated individuals; reducing population
level transmission in a community, and achieving and sustaining
elimination in areas of low transmission.
Malaria vaccine candidates have conventionally been clas-
siﬁed according to the stage of the life-cycle targeted [2].
Pre-erythrocytic Vaccines (PEV) target sporozoites and hepatic
forms in the liver, potentially providing protection from infec-
tion. Blood-stage Vaccines (BSV) target merozoites and infected red
blood cells, preventing episodes of symptomatic clinical malaria
and helping to clear blood-stage infections. Sexual-stage Mosquito-
transmission-blocking vaccines (SSM-TBV) target the sexual stages
of the Plasmodium parasite in the human or mosquito preventing
onwards transmission but not necessarily providing direct protec-
tion to the vaccinated individual. Both PEVs and SSM-TBVs are a
major focus of current research efforts [2]. PEVs and SSM-TBVs
are likely to have similar effects on a population level, causing
reductions in transmission in the community [3]. However, on an
individual level, it will be possible to measure the effect of PEVs, but
not the effect of SSM-TBVs which do not provide direct protection
to vaccinated individuals.
A number of candidate Plasmodium falciparum PEVs are cur-
rently under development based either on sub-unit approaches
tp://creativecommons.org/licenses/by/4.0/).
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here vaccination induces immune responses to targeted antigens
4–6], or whole parasite approaches where exposure to attenuated
porozoites may  induce strong, broad-spectrum immune responses
7–9]. RTS,S/AS01, which induces strong immune responses tar-
eting the circumsporozoite protein (CSP), is the most advanced
accine candidate having recently completed Phase III trials. Efﬁ-
acy against clinical malaria over one year of follow-up was  55.8%
97.5% CI: 50.6–60.4%) in children age 5–17 months [4], but was
igniﬁcantly lower in infants aged 6–12 weeks (31.3%, 97.5% CI:
3.6–38.3%) [5]. A number of candidate SSM-TBVs are also in devel-
pment against both P. falciparum and P. vivax, albeit at a much ear-
ier stage [10]. These can be divided into vaccines which target para-
ite surface antigens expressed either in the pre-fertilisation stages
ithin the human (for example Pfs48/45 and Pfs230) or the post fer-
ilization stage within the mosquito (for example Pfs25 and Pfs28)
11]. Only one of these candidates has gone through Phase I human
linical trials (Pfs25 [10] for P. falciparum and Pvs25 [12] for P. vivax).
The key parameters that must be measured in order to assess the
mpact of both PEV and SSM-TBV malaria vaccines are their efﬁcacy
against infection, clinical disease, or onwards transmission) and
he duration of protection (often measured in terms of half-life). For
EV clinical trials, vaccine efﬁcacy against both infection (through
ctive detection) and against clinical disease has been estimated
ith a high degree of statistical power [4,5,13]. However, in these
rials it has been more challenging to estimate the duration of
accine-induced protection [14,15]. For SSM-TBVs, studies to date
ave estimated the decrease in either the intensity or prevalence of
nward infection to mosquitoes, using membrane or direct feeds
16,17]. The challenges with measuring efﬁcacy in a ﬁeld setting
re considerable and no other trials of malaria interventions have
s yet attempted to directly measure impact on onward transmis-
ion in the community. A further challenge is to translate estimates
f vaccine efﬁcacy and duration of protection into their potential
ublic health impact. Although direct measurement can be made
rom PEV clinical trials, these are restricted by the characteristics of
he trial (transmission intensity, age proﬁles, duration of follow up),
nd cannot be easily extrapolated to other areas where vaccination
s being considered. For SSM-TBVs, there is unlikely to be a direct
stimate of public health impact from a trial. In both cases, mathe-
atical models of malaria transmission provide the most rational
pproach to estimate the public health impact of malaria vaccines
cross a wide range of settings [18–21].
Here, we present an overview of these challenges with a focus
n determining the public health impact of future malaria vaccines.
. Mathematical models of malaria transmission
Mathematical models can provide valuable tools for interpreting
he results of malaria vaccine trials, and for estimating the effective-
ess of malaria vaccination campaigns beyond trial settings. They
an account for the dynamics of transmission of malaria between
umans and mosquitoes, and the non-linear effects of reduc-
ng transmission through vaccination. A number of approaches of
arying complexity for modelling malaria transmission have been
uccessively pursued [19,20,22]. In this manuscript, we utilize a
reviously published model that accounts for the effect of vaccina-
ion on the acquisition of immunity to malaria [23]. The model is
ased on the Ross-MacDonald models [22] and accounts for the age
nd exposure dependent acquisition of immunity, heterogeneity
nd seasonality in exposure, and the impact of a range of interven-
ions.. Pre-erythrocytic vaccine efﬁcacy proﬁles
The safety, immunogenicity, and efﬁcacy of candidate vaccines
re estimated in clinical trials. Controlled human malaria infection3 (2015) 7544–7550 7545
(CHMI) studies can be used to obtain an initial estimate of efﬁcacy
in naïve volunteers. CHMI studies played a key role in the develop-
ment of the RTS,S malaria vaccine, providing early demonstrations
of safety [24], immunogenicity [25], and efﬁcacy against infection
[26]. Similarly, most second generation vaccine candidates will be
ﬁrst tested in CHMI trials [27].
The primary efﬁcacy endpoint for PEV CHMI studies has been
efﬁcacy against infection in the ﬁrst month after vaccination. Esti-
mates of efﬁcacy are conventionally presented as point estimates,
for example based on the proportion of vaccinated individ-
uals protected following challenges with P. falciparum infectious
mosquito bites [6,7,26]. Several studies have tested the dura-
tion of vaccine-induced protection from infection via re-challenge
after vaccination [8,26]. However the design of these studies often
involves selection of individuals for re-challenge conditional upon
being protected after a primary challenge. For example, when
Kester et al. [26] re-challenged RTS,S vaccinated participants 5
months after vaccination, participants were selected conditional
upon being protected during their ﬁrst challenge. Thus, care must
be taken when interpreting estimates of efﬁcacy at re-challenge
from CHMI trials, as individuals who  were protected following pri-
mary challenge are not necessarily representative of the population
as a whole.
Once efﬁcacy has been established in CHMI studies, ﬁeld trials
are needed to establish efﬁcacy under natural exposure conditions
in partially immune individuals residing in endemic areas. When
evaluating the efﬁcacy of a PEV, a number of endpoints are generally
considered, including P. falciparum infection, episodes of clinical
malaria, and episodes of severe malaria [28]. In clinical trials of PEVs
under conditions of natural malaria exposure, efﬁcacy is evaluated
by comparing the number of events in a vaccinated and a control
cohort over a given period of time. Point estimates of efﬁcacy can
be calculated as the rate ratio based on the number of episodes in
each cohort or as the hazard ratio based on time to episodes in each
cohort [29,30].
If there is substantial waning of vaccine efﬁcacy over time, then a
single point estimate of efﬁcacy will provide only part of the picture.
This is particularly important in the case of malaria vaccines where
components of naturally acquired and vaccine-induced immune
responses have been observed to be short-lived [15,31]. Fig. 1 pro-
vides an example of how vaccine efﬁcacy against infection may
wane over time, and the associated limitations of point estimates
of efﬁcacy. In particular point estimates of efﬁcacy against infec-
tion from CHMI trials at primary challenge may  differ from point
estimates from ﬁeld trials measured over a long time window due
to waning of efﬁcacy. We  deﬁne the vaccine efﬁcacy proﬁle as the
combination of the initial efﬁcacy against infection immediately
following vaccination and the pattern of waning of efﬁcacy over
time.
A number of statistical methods for assessing waning vaccine
efﬁcacy over time have been utilized. These include testing for
parametric or non-parametric patterns of waning [32,33], or meth-
ods for incorporating time-dependent covariates in proportional
hazards models such as Schoenfeld residuals or Anderson Gill mod-
iﬁcation [14,29,34]. Such estimation of patterns of waning has
predominantly been done in post hoc analyses. Future malaria vac-
cine candidates should therefore incorporate statistical methods
for estimation of duration of protection into earlier stages of their
trial design.
4. Example: The vaccine efﬁcacy proﬁle of RTS,SFig. 2 shows an example of how RTS,S-induced anti-CSP anti-
body titres, efﬁcacy against infection, and efﬁcacy against clinical
malaria change over time based on model estimates from data from
nine Phase II trials [15]. Similarly to naturally-acquired antibody
7546 M.T. White et al. / Vaccine 3
Fig. 1. Schematic example of a vaccine efﬁcacy proﬁle for a pre-erythrocytic vaccine
with efﬁcacy against infection waning exponentially from 70%. Estimates of efﬁcacy
against infection can be obtained through controlled human malaria infection stud-
ies  in laboratories or ﬁeld studies under conditions of natural malaria exposure over
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human and mosquito migration would be for each cluster to be sur-ome period of follow up (e.g., 0–6 months). Phase 2 studies typically provide point
stimates of efﬁcacy and are not designed to measure the duration of protection.
esponses [31], RTS,S-induced anti-CSP antibody titres wane over
ime (Fig. 2a). In particular waning titres follow a bi-phasic expo-
ential pattern with rapid waning in the ﬁrst 6 months followed
y a much slower rate of waning over the next 5 years. The short-
ived nature of the RTS,S induced antibody responses is in contrast
o vaccine-induced responses to other pathogens which can be very
ong-lived [35]. It has been hypothesized that boosting of vaccine-
nduced immune responses due to natural exposure may  occur
36], although this has never been observed for a malaria vaccine
n clinical trials.
RTS,S induced anti-CSP antibodies have been observed to be
ssociated with (i) protection from P. falciparum infection in con-
rolled human malaria infection (CHMI) studies in the laboratory
26,37]; (ii) protection from P. falciparum infection under condi-
ions of natural exposure in ﬁeld trials [38,39]; and (iii) protection
rom episodes of clinical malaria in ﬁeld trials [40]. Fig. 2b shows the
ose–response relationship between anti-CSP antibody titres and
rotection from infection based on model estimates from data from
hase II trials [15]. Notably, it is assumed that the dose–response
elationship is the same for all vaccinees and remains constant over
ime. Given the anti-CSP antibody dynamics and the dose–response
elationship, the vaccine efﬁcacy proﬁle against infection for RTS,S
an be estimated (Fig. 2c). This results in a bi-phasic exponential
attern with rapid waning in the ﬁrst 6 months followed by a
lower rate of waning over the next 5 years. There is substantial
ariation in efﬁcacy between individuals due to the variation in
accine-induced antibody titres.
Efﬁcacy against clinical malaria will change over time due to
aning efﬁcacy against infection (caused by waning anti-CSP anti-
ody titres), and due to the different rates of acquisition of natural
mmunity in the vaccine and control cohorts [41,42] (Fig. 2d). Indi-
iduals in the control cohort tend to experience more episodes
f clinical malaria than individuals in the vaccine cohort, and
ence develop natural immunity at a faster rate [43]. This differen-
ial acquisition of immunity between cohorts means that efﬁcacy3 (2015) 7544–7550
against clinical malaria decays faster than the underlying proﬁle of
efﬁcacy against infection. The prediction of negative efﬁcacy after
approximately 4 years is due to the higher incidence at that time in
the vaccine group compared to the control group as a consequence
of the delayed acquisition of clinical immunity. However, the total
number of cases averted by vaccination over the child’s lifetime is
always predicted to be positive, in agreement with data from the
Phase III trial of RTS,S [44]. We  deﬁne the decay of vaccine efﬁ-
cacy to be the combination of waning of vaccine-induced immune
responses and the higher levels of natural immunity in the con-
trol cohort compared to the vaccine cohort. As such, the decay of
vaccine efﬁcacy will depend on transmission intensity, with more
rapid decay in high transmission settings [45]. This pattern is clear
in site-speciﬁc analyses of data from Phase III trials of the RTS,S
vaccine [45], although there was insufﬁcient statistical power to
demonstrate statistical signiﬁcance.
5. Estimating the efﬁcacy of transmission-blocking
vaccines
A range of laboratory methods have been developed to assess
the effectiveness of SSM-TBV candidates [46]. The current gold
standard is the mosquito feeding assay whereby laboratory reared
mosquitoes are fed on infectious blood, either directly or through a
membrane feeder, before being dissected 8–10 days later to deter-
mine the number of parasites (oocysts) that have developed on the
midgut wall [16]. The difference in prevalence of oocyst between
the control (untreated) mosquitoes and those exposed to the SSM-
TBV candidate blood is used to estimate SSM-TBV efﬁcacy. Care
should be taken when analysing the results of these assays as the
efﬁcacy is thought to vary with the human-to-mosquito force of
infection [17].
Once a SSM-TBV has been shown to be safe and there is evidence
of transmission reducing ability from mosquito feeding studies,
ﬁeld trials are needed to demonstrate impact on onward transmis-
sion. In contrast to the Phase IIb/III trials undertaken for PEVs, a
trial for SSM-TBV will need to be designed to estimate the impact
on onward transmission. One approach is to use mosquito infec-
tion as a trial endpoint as a surrogate for onward infection. This
would involve feeding studies using either membrane or direct
feeding on trial participants [16]. A key advantage to such studies
is their relative simplicity compared to the more complex designs
needed to estimate impact on transmission (see below). How-
ever, the relationship between human and mosquito infection is
not straightforward and may vary between settings [47]. It there-
fore remains unclear whether regulatory agencies would accept
mosquito endpoints when granting licensure.
As for PEVs, early Phase II trials tend, by their design, to focus on
estimates of initial efﬁcacy, and not duration of protection. Here,
exactly the same principles apply as those outlined for PEVs and a
similar decay proﬁle may  be predicted (Fig. 1). To provide an esti-
mate of the duration of efﬁcacy, a subset of those enroled in the full
ﬁeld trials should be repeatedly sampled over a longer time period.
If it is decided that a Phase III clinical trial is required to prove
effectiveness then a cluster-randomised control trial (CRCT) will be
needed. It is unclear exactly what scale a CRCT should be carried
out at to ensure the community beneﬁts of a SSM-TBV are ade-
quately captured [48]. Ultimately it will depend on the population
density of the area (small compact versus sparsely populated vil-
lages), the availability of mosquito breeding sites (whether they
are ubiquitous or concentrated in one place) and the degree of
human movement. One approach to try and mitigate the impact ofrounded by a buffer-zone (the so called “fried-egg” design) where
the intervention is given but whose residences do not contribute
to the primary endpoint of the study [48].
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Fig. 2. Antibody dynamics and vaccine proﬁle for RTS,S/AS01. Figures are based on mathematical models ﬁtted to data from Phase II trials of RTS,S [15]. (a) Following
vaccination with RTS,S/AS01 the waning of anti-CSP antibody titres can be described by a bi-phasic exponential distribution with rapid waning in the ﬁrst three months
followed by slower waning. (b) Increased anti-CSP antibody titres are associated with increased probability of preventing infection. The dose-response relationship is assumed
to  be the same for all individuals. (c) Efﬁcacy against P. falciparum infection (d) At an EIR = 20 bite per year, efﬁcacy against clinical malaria is predicted to decay to zero
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From a statistical point of view, the objective when designing a
rial is to maximize statistical power. Low transmission areas are
herefore generally not appropriate since only a small number of
ndividuals are expected to become infected. Statistical power in
eneral increases as the incidence of malaria increases. However,
articipants that develop disease during the trial will need to be
reated, and it has been proposed that these treated individuals
hould be subsequently censored (removed) from the trial for a
eriod of a few weeks to prevent the prophylactic effects of the
rug from biasing estimates of susceptibility to malaria [48]. Hence,
f effectiveness is measured as a reduction in clinical incidence then
tatistical power is likely to plateau at moderate to high transmis-
ion (Fig. 3). This means that the most suitable place to conduct
 trial based on clinical incidence endpoints may  be in a moder-
te transmission setting. Although the effects of censoring mean
hat moderate transmission settings are likely to be optimal for
he evaluation of SSM-TBVs, from a public health point of view the
ffectiveness will be based on the total number of clinical cases
verted.
In a SSM-TBV trial, participants receiving the vaccine acquire no
irect protection from infection, and hence the appropriate end-
oint is some measure of infection in the community. Whilst the
ime to the ﬁrst clinical episode is the easiest endpoint to mea-
ure, its interpretation is complicated by the differential rates ofy against infection for comparison. The difference between efﬁcacy against clinical
he control cohort compared to the vaccine cohort, which is accounted for using a
ote the 50% and 95% ranges due to variation in antibody titres and efﬁcacy.
acquisition of natural immunity by age and transmission site. An
alternative is to use a direct measure of incidence of infection, for
example, through active detection of infection in order to include
new asymptomatic infections. However if all participants in the
trial are treated following infection, then transmission in the com-
munity as a whole is likely to be modiﬁed, necessitating the same
procedure to be carried out in both arms of the study to prevent
biased estimates of vaccine efﬁcacy. To overcome the problems of
the clinical trial protocol in itself causing a change in transmission
it has been suggested that only a small percentage of the cluster, a
sentinel population, is monitored over time [48]. This would reduce
the epidemiological impact of active case detection and treatment,
though comes at the cost of substantially increasing cluster size and
overall ﬁnancial costs.
An important consideration when designing a Phase III trial
is ensuring that the results are representative of the settings in
which implementation is likely to occur. For SSM-TBVs, this results
in a number of conundrums. Firstly, variation in transmission,
seasonality, past history of interventions, immune status of the
population, and genetic variation of individuals may  all affect the
ultimate efﬁcacy of a vaccine. Capturing this variation in a trial
is important for safety reasons, as well as for obtaining accurate
efﬁcacy estimates. However, variation between clusters decreases
statistical power and hence necessitates more enrolled individuals,
7548 M.T. White et al. / Vaccine 33 (2015) 7544–7550
Fig. 3. Cases of clinical malaria averted in a clinical trial of a candidate sexual-stage mosquito transmission-blocking vaccine when detected cases are temporally censored
following treatment. Malaria transmission across a range of P. falciparum parasite rates (PfPR2–10 measured in children aged 2–10 years of age) was simulated in vaccinated
and  control populations of size 10,000 over a one year period using a mathematical model [23]. In the vaccinated cohort, a transmission blocking vaccine with initial efﬁcacy
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Ff  80%, waning exponentially with a 1 or 2 year half-life, was implemented at 90% c
ill  lead to more episodes of clinical malaria being averted (a), and hence an increas
umber of treatments administered (b) and the time spent under chemoprophylaxis
ncreasing the cost of such a trial. Secondly, the setting where a par-
ially efﬁcacious TBV is likely to have the greatest impact is at low
ransmission, since in such settings the vaccine could potentially
nterrupt transmission leading to community beneﬁt through herd
mmunity (whereby unvaccinated people are protected from infec-
ion by vaccinated individuals). However, the statistical power of
rials in such settings is very low. Thus, it is likely that the true value
f TBVs will only become apparent following licensure and Phase
V follow-up.
. Predicting population impact
The population impact of a vaccine is dependent on the epi-
emiological setting in which it is deployed. Early phase clinical
rials can estimate vaccine efﬁcacy in individuals, but the effective-
ess at reducing transmission and the number of cases in non-trial
opulations will be modiﬁed by factors such as transmission inten-
ity, seasonality, mosquito species, coverage, compliance patterns,
nd the use of other control interventions. Financial constraints
ill limit the range of epidemiological settings where clinical tri-
ls can be undertaken. Mathematical models are therefore needed
o extrapolate the effectiveness of a vaccine candidate to other
ettings where they are likely to be utilized. Equally it should be
ealized that Phase III clinical trials are dependent on the epidemi-
logical and healthcare setting in which they took place and that
accine effectiveness once deployed in the general population may
e higher or lower than previously measured.
Key to understanding the population level impact of vaccina-
ion is the current level of transmission. The appropriate measure
f transmission intensity to use will depend on the type of vaccine
nder investigation, but in most settings, the entomological inocu-
ation rate (EIR, the number of infectious bites per person per year)
rovides a good metric and the malaria prevalence (as measured by
icroscopy, RDT, or PCR) a convenient alternative. Crucially, both
re related to the basic reproductive number, R0, which provides
n indication of the vaccine effectiveness required to interrupt
ransmission [49]. One important consequence of the correlation
etween public health impact and transmission intensity is that
here is no single “target” vaccine efﬁcacy to achieve a given goal.
or example, for RTS,S, whilst the lowest efﬁcacy against diseasee across the entire population. Trials implemented in higher transmission settings
lihood to detect an effect. However, increasing transmission intensity increases the
ng the overall number of cases detected in the cohort to plateau at high endemicity.
was observed in the highest transmission settings, the greatest
public health impact was  also observed in these settings due to
the higher underlying burden [45]. Similarly, the minimum efﬁcacy
required to achieve elimination will be lower in very low transmis-
sion settings, with vaccines alone unlikely to interrupt transmission
in moderate or high settings.
The current transmission intensity will depend on the coverage
of other interventions (e.g., vector control and ﬁrst-line treatment)
in place. Therefore an area might have low transmission intensity
either because there was low endemicity at baseline due to low
mosquito densities or because other interventions have success-
fully reduced transmission [50]. It is not immediately clear whether
it is just the current level of transmission that will determine vac-
cine effectiveness or whether the population’s history of infection
will have an inﬂuence due to the previous acquisition of immunity
(which may  or may  not interact with the vaccine induced immu-
nity). Regardless, any new vaccine will need to be assessed in light
of the ongoing background of other interventions and access to
ﬁrst-line treatment.
The effectiveness of vaccines with relatively short periods of
protection will also vary according to the seasonality in malaria
transmission. This seasonality could be driven by ﬂuctuations in
mosquito numbers or the use of other time-varying interventions
such as indoor residual spraying. In areas of high seasonality,
the shorter the period of optimal vaccine protection the more
important it will be to time vaccination appropriately, with the
maximum impact on the number of cases typically occurring imme-
diately prior to the peak in transmission. Other facets of mosquito
behaviour such as heterogeneity in biting will also inﬂuence pop-
ulation level effectiveness. For example, if there are hotspots of
transmission and some people are bitten substantially more than
others, then the relationship between disease prevalence and trans-
mission intensity becomes increasingly non-linear [47,51]. Thus
the ability of a vaccine campaign to reduce transmission also varies
according to whether the people that are bitten the most had
received the vaccine. It is therefore important to assess these het-
erogeneities as far as possible in clinical trials.
Integral to the effectiveness question is the potential delivery
strategy for a new vaccine and the likely coverage of the target
population that can be achieved. This will depend on whether
M.T. White et al. / Vaccine 3
Fig. 4. Predicted population impact of vaccination campaigns. P. falciparum parasite
rate (PfPR2–10) in children aged 2–10 years of age is simulated using a mathematical
model of malaria transmission dynamics [23] in a seasonal setting with baseline
PfPR2–10 = 10%. The black curve denotes the scenario in the absence of vaccination.
The red curve is the predicted PfPR2–10 following the introduction of a PEV with 80%
efﬁcacy against infection and a 2 year half-life through the expanded programme of
immunization (EPI) at 90% coverage. The green curve shows the effect on PfPR2–10 of
the  same PEV administered through a mass vaccination campaign at 90% coverage
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[16] Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-
Ambene PH, et al. Mosquito feeding assays to determine the infectiousnessvery 3 years. The blue curve shows the effect of mass vaccination every 3 years at
0% coverage of a SSM-TBV with 80% efﬁcacy and a 2 year half-life.
he goal of the programme is to reduce morbidity or to inter-
upt transmission. The latter will require a more comprehensive
egimen and the minimum population coverage needed will vary
etween settings and according to vaccine proﬁle. Cost will clearly
e important for both of the vaccine itself, but also of the deliv-
ry strategy. For example, vaccines can be added to the WHO
xpanded Program on Immunisation (EPI) to directly protect young
hildren from disease, but the limited age range might not be
uitable for all types of vaccines if the aim is to reduce population-
evel transmission. As such, EPI delivery is appropriate for PEVs
ut it is unlikely to be suitable for TBVs as older children and
dults contribute signiﬁcantly to the human reservoir of infection
52].
Fig. 4 shows a comparison using a mathematical model [23]
f vaccination campaigns with PEVs and SSM-TBVs in a setting
f moderate and seasonal malaria transmission intensity. Despite
roviding substantial protection to vaccinated children, a PEV
dministered through the EPI is expected to have limited impact
n population level transmission. Mass vaccination campaigns
ith PEVs or SSM-TBVs may  cause large reductions in population
evel malaria transmission, although the effect size will depend
n transmission intensity, campaign coverage, vaccine efﬁcacy and
uration of protection.
. Conclusions
The wide range of potential roles for malaria vaccines is a
onsequence of the diversity of approaches for targeting the Plas-
odium parasite, which has multiple life stages in both the human
nd vector hosts. This is in contrast to viral pathogens such as
easles with much simpler lifecycles. In the past, the complex
ature of the Plasmodium lifecycle has been viewed as a chal-
enge to the malaria vaccine development effort. However, it also
rovides opportunities to target the malaria parasite on multi-
le fronts. One area in which research is perhaps lacking is how
est to combine PEVs, BSVs, and TBVs. Future research into the
[3 (2015) 7544–7550 7549
potential synergies of such an approach could prove valuable
[53,54].
Development of malaria vaccines has been rapid over the last
decade, with a wide range of candidates in the current pipeline [2].
Furthermore, the ﬁrst malaria vaccine to complete Phase III trials,
RTS,S, could become available to endemic countries within the next
three years. Much has been learned during the development of the
RTS,S vaccine, in particular in relation to the variability in vaccine
efﬁcacy between individuals and between individuals residing in
different epidemiological settings. The implementation of Phase II
and Phase III trials of RTS,S in greater than 20,000 participants in
P. falciparum endemic countries has come at considerable ﬁnancial
cost, but at the same time provides a solid research basis to speed
the development and evaluation of the next generation of malaria
vaccines.
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